With the appointment of outsider and Frenchman Pascal Soriot to the CEO hot seat at AstraZeneca PLC, the troubled U.K. multinational is gaining an executive experienced in managing the merger of biotechs with multinationals.
This experience might well come in useful over the coming months, with regard to both old and new acquisitions. AstraZeneca’s Gaithersburg, Md.-based subsidiary, MedImmune LLC, is perceived as not yet having delivered on its promise after AstraZeneca spent $15
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?